Vitrolife AB (publ) (VTRLY) Stock Price & Analysis
Vitrolife AB (publ) (VTRLY) — price $10.24 (0.00%), as of the Nov 19, 2026 trading session; market cap $1.36B.
Educational signal · not a buy or sell recommendation · How to read this
Vitrolife AB (publ) · VTRLY
Vitrolife AB (publ) is a medical device company focused on assisted reproduction. The company develops, produces, and markets products for in vitro fertilization and related treatments globally.
Price as of Nov 19, 2026
Key Statistics
Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $10.24 | |
| Change on the day | 0.00% | |
| 52-week range | $9.50 – $18.55 | |
| Market capitalisation | $1.36B | |
| Shares traded on the day | 6 |
Price & events
Other perspectives
Council score for Vitrolife AB (publ) (VTRLY): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
4 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: May 26, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Apr 29, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Apr 29, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Vitrolife AB (publ) (VTRLY), and what does it report?
Short answer · as of
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Vitrolife AB (publ) (VTRLY) is the company analyzed here. It employs 1,151 people and is led by Rickard Ericsson. In Q3 FY2026 it reported revenue of kr871M and net income of kr124M. The market values it at $1.36B.
What do the latest results show for Vitrolife AB (publ) (VTRLY)?
Short answer · as of
The most recent reported quarter, Q3 FY2026, carried revenue of kr871M.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q3 FY2026 | kr871M | kr124M | kr0.93 (diluted) |
| Q2 FY2026 | kr857M | kr129M | kr0.95 (diluted) |
| Q1 FY2026 | kr807M | kr101M | kr0.74 (diluted) |
| Q4 FY2025 | kr891M | -kr5.31B | -kr39.24 (diluted) |
What are the financial strengths and risks for Vitrolife AB (publ) (VTRLY)?
Short answer · as of
The distress and quality screens read Altman Z 0.75 · Piotroski F 6. Trailing ratios: ROE -61.6% · ROA -43.4% · current ratio 3.68 · earnings yield -31.0% · free-cash-flow yield 3.8%.
Data-derived red flags
- Financial-distress signal — its Altman Z-Score of 0.75 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-61.6%) — the business is not currently generating profit on shareholder capital.
The records behind this page
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held VTRLY in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported VTRLY in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
Vitrolife AB (publ) Stock: Key Questions Answered
These answers are editorial: 1 of these 8 answers is drawn from the VTRLY research dossier (written Mar 17, 2026 by gemini-2.0-flash); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.
Is VTRLY a good stock to buy?
Stock Expert AI does not rate VTRLY buy, sell or hold. Vitrolife AB (publ) has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the VTRLY stock price today?
The last price recorded for Vitrolife AB (publ) (VTRLY), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What do analysts say about VTRLY stock?
Analyst coverage of VTRLY stock is limited due to its OTC listing. However, the company's position in the growing assisted reproduction market and its comprehensive product portfolio are generally viewed positively. Key valuation metrics, such as the negative P/E ratio and profit margin, raise concerns about current profitability.
What are the key factors to evaluate for VTRLY?
Evaluate VTRLY on fundamentals, analyst consensus, and risk factors. Presence in Europe, Asia, and the Americas provides a diverse revenue base. Not financial advice.
How frequently does VTRLY data refresh on this page?
VTRLY's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven VTRLY's recent stock price performance?
Vitrolife AB (publ) (VTRLY) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Comprehensive product portfolio covering the entire IVF process. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider VTRLY overvalued or undervalued right now?
Vitrolife AB (publ) (VTRLY) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research VTRLY before investing?
Before investing in Vitrolife AB (publ) (VTRLY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 13 figures on this page — 8 from Financial Modeling Prep (FMP) and 5 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com